Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

Source: OncLive, September 2020

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.

The study randomized patients with previously untreated, unresectable, stage III or IV melanoma 1:1:1 to receive 1 mg/kg of nivolumab (Opdivo) plus 3 mg/kg of ipilimumab (Yervoy) for 4 doses, followed by 3 mg/kg of nivolumab; 3 mg/kg of nivolumab plus ipilimumab-matched placebo; or 3 mg/kg of ipilimumab for 4 doses plus nivolumab-matched placebo until progression or unacceptable toxicity, says Shoushtari.

Less common subtypes, such as mucosal and acral melanoma, were included in the study, but the majority of patients had cutaneous melanoma, adds Shoushtari. Notably, patients with uveal melanoma were excluded.

READ THE ORIGINAL FULL ARTICLE